Commentary on "Targeting B7-H3 inhibition-induced activation of fatty acid synthesis boosts anti-B7-H3 immunotherapy in triple-negative breast cancer"

<p>Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype characterized by limited treatment options and poor prognosis. Immune checkpoint blockade, particularly via programmed cell death protein-1/programmed death-ligand 1 inhibition, has improved outcomes in selected patients with TNBC; however, resistance remains a major barrier. Recent studies have identified B7-H3 (CD276) as a key immune-suppressive molecule overexpressed in TNBC, correlating with…